Listen now
Key takeaways
- MedTech companies often fail due to commercialization gaps, not just technological shortcomings, such as improper sequencing of fundraising, regulatory strategy, sales, and market entry.
- Inconsistencies across pitch decks, websites, evidence, and buyer messaging immediately create doubt and are a significant commercialization gap.
- Claims outpacing available evidence, or an "evidence gap," is a critical issue that investors pressure-test during startup evaluations.
- Unclear identification of the target buyer can dilute a company's message and lead to taking on the wrong customers, hindering commercial success.
- Cybersecurity and AI introduce new layers of risk and complexity to medical device commercialization, requiring careful consideration.
- A consistent story about who the company is, who it serves, and the problem it solves is crucial for effective commercialization.
Why can a MedTech company have promising technology, a strong team and investor interest, yet still lose momentum when it matters most?
Ryan Roghaar joins Christian Espinosa to examine the commercialization gaps that can quietly weaken a medical device company long before the technology itself becomes the problem.
Ryan explains why companies often move through fundraising, regulatory strategy, sales and market entry in the wrong sequence, and why inconsistencies between a pitch deck, website, evidence and buyer messaging can immediately create doubt.
The conversation explores what happens when claims outpace evidence, why MedTech companies struggle to define exactly who they are selling to, and how cybersecurity and AI are adding entirely new layers of risk to commercialization.
In This Episode:
07:43 Why Ryan moved into MedTech
10:32 Moving from marketing agency to MedTech consultancy
11:32 Why devices fail outside the technology itself
12:41 Does MedTech commercialization follow a sequence?
16:08 The evidence gap inside MedTech companies
17:10 How investors pressure-test startups
19:55 When a company tells four different stories
23:36 Can cybersecurity become a commercial differentiator?
24:11 Why medical device hacking feels different
27:24 Cybersecurity risks from MRIs to brain implants
32:21 The three biggest commercialization gaps Ryan is seeing
35:57 Why unclear buyers dilute your message
39:08 The pressure to take the wrong customer
42:47 Ryan’s three key takeaways for MedTech companies
Notable quotes
“MedTech companies will have promising technology, a strong team, investor interest, yet still lose momentum when it matters most, because the technology itself becomes a problem later.”
“The number one most important thing that I see consistently is a story that has four different components and four different audiences. And they tell a different story to each one.”
“Cybersecurity for medical devices is such a different animal because this isn't just someone stealing your data, this is someone potentially taking over a medical device and causing harm.”
“If you don't know who your buyer is, you can't tell a compelling story, because your story is diluted with all of these people that you 'might' serve.”
Frequently asked questions
Bring this work to your device
Need help with penetration testing?
Blue Goat Cyber delivers medical device penetration testing for medical device manufacturers - from threat modeling to FDA-ready reports.
Medical Device Penetration TestingMore on Penetration Testing
Keep listening
-
Episode 78
Productivity, Psychological Safety and AI with Sarah Ohanesian and Jeff Gibbard
With Sarah Ohanesian
-
Episode 77
From Science Fiction to Visual Prosthesis with Frederik Ceyssens
With Frederik Ceyssens
-
Episode 76
Building Medical Devices Right the First Time with Helen Souris
With Helen Souris
-
Episode 75
What MedTech Can Learn from the Casino Industry with Melissa Aarskaug
With Melissa Aarskaug